Wiener Medizinische Wochenschrift

, Volume 166, Issue 13–14, pp 424–430 | Cite as

Autoimmune gastritis

  • Stefanie Kulnigg-Dabsch
Open Access
main topic


Autoimmune gastritis is a chronic inflammatory disease with destruction of parietal cells of the corpus and fundus of the stomach. The known consequence is vitamin B12 deficiency and, consequently, pernicious anemia. However, loss of parietal cells reduces secretion of gastric acid which is also required for absorption of inorganic iron; thus, iron deficiency is commonly found in patients with autoimmune gastritis. This usually precedes vitamin B12 deficiency and is found mainly in young women. Patients with chronic iron deficiency, especially those refractory to oral iron therapy, should therefore be evaluated for the presence of autoimmune gastritis.


Iron deficiency Vitamin B 12 deficiency Autoimmune gastritis Chronic atrophic gastritis Gastric cancer 



autoimmune gastritis


parietal cell antibodies



Die Autoimmungastritis ist eine chronisch-entzündliche Erkrankung mit Verlust der Parietalzellen im Corpus und Fundus des Magens. Bekannte Folgen sind ein Vitamin-B12-Mangel und folglich eine perniziöse Anämie. Der Verlust der Parietalzellen führt jedoch auch zu einer Reduktion der Magensäure, die für die Aufnahme von anorganischem Eisen benötigt wird. Daher ist Eisenmangel eine häufige Diagnose bei Patienten mit Autoimmungastritis. Oft findet man diesen vor dem Auftreten eines Vitamin-B12-Mangels, insbesondere bei jüngeren Frauen. Patienten mit chronischem Eisenmangel sollten daher auf Marker einer Autoimmungastritis untersucht werden, vor allem wenn sie nicht auf eine orale Eisensubstitution ansprechen.


Eisenmangel Vitamin-B12-Mangel Autoimmungastritis Chronisch atrophische Gastritis Magenkarzinom 


Autoimmune gastritis (AIG) is a chronic inflammatory disease of the stomach, finally presenting with atrophy of the mucosa. It is very important to note that chronic atrophic gastritis is not synonymous with AIG, as atrophy of the mucosa is the final result of a chronic inflammatory disease independent of etiology, which is mainly Helicobacter pylori gastritis or AIG. In contrast to Helicobacter pylori-, stress-, or drug-induced gastritis, inflammation and continuous atrophy is restricted to corpus and fundus in AIG. This is due to the fact that the autoimmune reaction in AIG targets parietal cells. Parietal cells are epithelial cells located in the glands of the corpus and fundus but not in the antrum, and produce hydrochloric acid and intrinsic factor. The acidification of the stomach is primarily managed by the gastric H+/K+ ATPase, the proton pump, which is the causative autoantigen and which is recognized by CD4+ T cells [1]. The chronic inflammation leads to an atrophy of the mucosa, with a decrease and final total loss of parietal cells during progression of disease. This results in increased pH of the stomach and loss of intrinsic factor, which is produced by parietal cells. Intrinsic factor is required for uptake of vitamin B12 and vitamin B12 deficiency (pernicious anemia) is a known consequence of AIG. As early as 1909, “achylia gastrica” was identified as the underlying cause of iron deficiency by Faber [2]. Thereafter it was long ignored, until the end of the last millennium when several authors addressed the question of iron deficiency and AIG in their studies [3, 4].

AIG and iron deficiency

The total iron content of a healthy adult is about 4 g. Two thirds are bound in hemoglobin; the vast majority of that remaining is stored in ferritin in all types of cells. Only a few milligrams are actively circulated via binding to transferrin. Physiological daily iron loss via shredded cells of skin and gastrointestinal mucosa as well as hair loss is about 1–2 mg; the same amount is taken up by enterocytes of the duodenum and upper jejunum. Iron metabolism is only regulated via uptake as there is no active excretion mechanism. A distinction is drawn between uptake of heme (meat) and non-heme iron. Heme iron is taken up via a heme receptor [5] into the enterocyte, where iron is then released. Non-heme iron uptake is more complex and about 80 % of dietary iron is non-heme iron [6]. Inorganic iron in all kinds of food is in its ferric (Fe3+) form and must be reduced to ferrous (Fe2+) before it can enter the enterocytes via the divalent metal transporter 1. This is managed by enzymatic reduction (duodenal cytochrome B), but several other factors also reduce iron, of which the most important is gastric acid.

Iron deficiency occurs if there is an imbalance of iron uptake and iron loss. The most common cause is increased loss due to acute or chronic bleeding (gastrointestinal, GI, bleeding; augmented menstrual bleeding). Besides loss of iron, decreased iron absorption is causative of iron deficiency. This might be due to inflammation at the site of iron uptake, which is found in Crohn’s disease and also coeliac disease. The importance of normal gastric secretion and acidity for uptake of iron has been reported in several studies [7, 8, 9]; also patients with gastrectomy are known to suffer from iron deficiency anemia [10]. Abnormal gastric secretin in patients with AIG is well described [2, 11] and led to the term “achylia gastrica”. Besides the absence of gastric acid, ascorbic acid in food sources is also important for iron uptake. In AIG this was found to be reduced. It is hypothesized that ascorbic acid is destroyed due to the higher gastric pH [12]. On the other hand, nutritional iron (ferric and ferrous) is generally bound to proteins and needs to be released for uptake. Gastric acid is therefore needed. Iron deficiency as a result of AIG was already described more than a century ago [13, 14]. Cook et al. evaluated the absorption of dietary non-heme iron in controls vs. AIG patients and found a reduced iron uptake (19.8 vs. 35 %) [8]. In a subgroup of patients the effect of addition of gastric juice to the test meal in iron absorption was examined: an increased iron uptake of more than twofold could be found, whereas neutralized gastric juice did not change iron absorption. Likewise, AIG patients are typically refractory to oral iron therapy [4, 15].

In summary, decreased uptake of inorganic iron due to missing reduction of ferric iron, missing degradation of iron–protein complexes as a result of lack of gastric acid, and reduced levels of ascorbic acid are the likely causes of iron deficiency in AIG.

Vitamin B12 deficiency in AIG is not only caused by loss of intrinsic factor if parietal cells are destroyed, but is also due to loss of gastric acid, which is needed for release of the vitamin from food sources. Pernicious anemia is a rather late finding in AIG and diagnosed mainly in elderly patients [11]. This might be explained by minimal turnover (2–3 µg per day) with large stores (2–5 mg) on one hand, and on the other hand, by the fact that vitamin B12 absorption is additionally reduced with age.

Although AIG impairs both iron and vitamin B12 uptake, iron deficiency will be found at a younger age and many years before the development of pernicious anemia [11], as in younger (premenopausal) woman menstrual blood loss (and pregnancies) is an additional burden to iron metabolism. This is supported by results of several epidemiologic studies [3, 4, 15, 16].

Clinical presentation

Symptoms vary during the course of disease (Table 1). Contrary to other types of gastritis (B or C), gastritis-associated symptoms such as pain are not in the foreground; furthermore, AIG patients have no risk of developing a gastric or duodenal ulcer. Achlorhydria itself leads to symptoms such as delayed gastric emptying, small intestinal (and gastric) bacterial overgrowth, and an increase in GI infections such as clostridium difficile colitis. The main clinical manifestation of AIG is known to be pernicious anemia; however, Hershko et al. showed in 2006 that the predominant hematologic manifestation of patients with AIG is iron deficiency anemia, as defined by microcytic anemia which was present in 50 % of patients [16]. Symptoms of iron deficiency arise independently of and prior to anemia-related symptoms, and include fatigue, restless legs syndrome, brittle nails, hair loss, impaired immune function, and impaired wound healing. Anemia (irrespective of etiology) results in shortness of breath, dizziness, tachycardia, lightheadedness, and decreased cognitive and physical function. In pregnancy it can lead to poor pregnancy outcome with early birth and underweight newborns. Very typical for AIG is the refractoriness to oral iron therapy.

Besides hematologic symptoms, patients who developed vitamin B12 deficiency will suffer from gastrointestinal and neurological complaints such as malabsorption, diarrhea, weight loss, glossitis, peripheral numbness, paresthesia with subsequent development of weakness, and ataxia. Furthermore, mental disturbances ranging from forgetfulness to psychosis may arise. Untreated pernicious anemia is fatal [11].

As AIG is associated with other autoimmune diseases, symptoms such as fatigue may also be due to thyroid hypofunction in the presence of autoimmune thyroiditis (Hashimoto’s disease). Patients newly diagnosed with AIG should therefore be screened for thyroid diseases. More rarely, diabetes type 1 or Addison’s disease is found, and should be taken into account if symptoms do not resolve after treatment of deficiencies.


Data on incidence are difficult to obtain, as most patients will be asymptomatic for years due to late and unspecific development of symptoms. The study of Zhang found a prevalence of 19.5 % of positive parietal-cell antibodies (PCA) in patients (recruited during general health check-up at general practitioner), with numbers increasing with age and in patients positive for Helicobacter pylori, but with no difference between the genders [17]. Atrophic gastritis as defined by serological testing (pepsinogen I and pepsinogen I/II ratio) was found in 46 % of patients positive for PCA vs. 18 % in those negative. However, only patients between the age of 50 and 74 years were included (mean 62 years); therefore, this study might overestimate the number as prevalence seems to increase with age. The study of Cabrera included randomly selected individuals from the Canary Islands between the age of 18 and 75 years. A total of 7.8 % were tested positive for PCA; higher numbers were found for women, with no age difference [18]. There are a number of other studies assessing the prevalence of pernicious anemia or chronic atrophic gastritis; however, these do not reflect the true prevalence for AIG, as pernicious anemia is the end stage of disease and chronic atrophic gastritis is not exclusively due to AIG but mainly due to Helicobacter pylori infection.

Helicobacter pylori has even been discussed as trigger for AIG because of the molecular mimicry between H. pylori antigens and the gastric H/K ATPase [19, 20]. Although several studies have examined this issue, the role of Helicobacter pylori in pathogenesis remains unclear.

In contrast, the association between AIG and other autoimmune diseases is clearly known. Especially in patients with autoimmune thyroiditis, where the incidence increases to up to ~35 % [21, 22]. But also other autoimmune diseases such as diabetes type I, Addison’s disease, and vitiligo show an increased risk [23, 24, 25].

Epidemiologic data on the prevalence of AIG in patients with (iron deficiency) ID are available from five studies (Table 2): Dickey et al. studied 41 patients with iron deficiency anemia (IDA). Atrophic gastritis diagnosed by histological evaluation was found in 20 % (n = 8) of patients, of whom 6 had detectable antibody levels against intrinsic factor or parietal cells, one patient had detectable Helicobacter pylori, and the last patient had neither, resulting in a prevalence of AIG of 15 % [3]. In the study of Hershko, a higher incidence of AIG in patients with IDA could be found. One hundred and fifty patients with iron deficiency anemia of unknown etiology were included. Positive levels of PCA together with hypergastrinemia pointing to AIG were diagnosed in 27 % [4]. The study of Annibale evaluated the presence of atrophic gastritis in IDA (26 %); however, unfortunately, no characterization of atrophy (antrum or body/fundus) or further testing for AIG was done [15]. As 13 of the 19 patients (total 18 %) were positive for Helicobacter pylori, the incidence for AIG might be lower. In a British study, 12 of 44 (27 %) anemic patients with iron deficiency were positive for PCA [26]. The latest study of Kulnigg-Dabsch evaluated the cause of iron deficiency (with or without anemia) in 409 patients and found positive PCA in 18.5 %. Patients with positive PCA had lower hemoglobin and ferritin levels and were more prone to restless legs syndrome [27]. Furthermore, patients with IDA and AIG seems to be younger and predominantly female [16].
Table 1

Prevalence of autoimmune gastritis in patients with iron deficiency



Prevalence of autoimmune gastritis in iron deficiency




Prevalence (%)

Dickey et al. [3]


Iron deficiency anemia

Histology and pos PCA/IFA


Hershko et al. [4]


Iron deficiency anemia

↑ Gastrin and pos PCA


Annibale et al. [5]


Iron deficiency anemia

Histology (body atrophy)


Kaye et al. [26]



Iron deficiency anemia

Histology (body atrophy)




Kulnigg-Dabsch et al. [27]


Iron deficiency



PCA parietal cell antibodies, IFA intrinsic factor antibodies, pos positive

Table 2

Symptoms of iron deficiency, vitamin B12 deficiency, and anemia


Iron deficiency

Vitamin B12 deficiency




Shortness of breath

Restless legs syndrome

Peripheral neuropathy


Attentiveness disorder



Brittle nails

Spinal ataxia

Decreased physical function

Hair loss


Decreased cognitive function

Sleeping disorder






ID iron deficiency, IDA iron deficiency anemia

Diagnosis of AIG

Gold standard for diagnosis of AIG is gastroscopy, with separately collected biopsies of antrum and corpus with typical histological findings [28]. The endoscopic appearance of AIG may not be different from the healthy situation during early phases of disease; however, with increasing loss of the oxyntic mucosa, pseudopolyps might be seen which mimic relatively normal mucosa while the surrounding is atrophic [29]. If extensive atrophy is present, rugal folds are flattened, submucosal vessels may be visible, and pseudopolyps or polyps (hyperplastic or adenomatous) might be present ([30, 31]; Fig. 1). Typical histological findings change during the course of disease. In early phases, lymphocytic and plasma cell infiltration of the oxyntic mucosa is found, mainly multifocal with accentuation in the deeper, glandular portion [32]. Oxyntic glands might be destroyed fragmentary, and parietal cells show pseudohypertrophic changes. As these features are non-specific, pathologists might misinterpret findings without knowledge of serum markers such as PCA. In the study of Pittman, metaplasia, full-thickness chronic inflammation, and/or oxyntic destruction were found as early unspecific changes [33]. Furthermore, hyperplasia of endocrine cells is an early finding in AIG [31]. After progression of disease, a diffuse lymphoplasmatic infiltration of the lamina propria with marked atrophy of the oxyntic glands is found. Intestinal metaplasia becomes noticeable. End stage of disease is defined by distinct reduction or total loss of oxyntic glands; furthermore, pseudopolyps or hyperplastic polyps can be found as well as pancreatic or intestinal metaplasia. On the contrary, the inflammatory reaction is reduced in comparison to earlier stages of disease ([30]; Fig. 2). Immunohistochemical staining of G cells (gastrin) might help to identify the site of biopsy if samples were not sampled separately or labeled correctly, as diagnosis of AIG can only be made from corpus or fundus biopsies.
Fig. 1

Endoscopic picture of autoimmune gastritis. a Incipient atrophy of corpus. b Mucous covering of gastric mucosa, pseudopolyps in corpus and fundus

Fig. 2

Histologic picture of end stage autoimmune gastritis (hematoxylin and eosin staining, X200). a Total loss of parietal cells with moderate inflammatory cells consisting of mainly mononuclear cells but also eosinophil granulocytes. b Foveola and gland bodies with total loss of parietal cells and only discrete inflammatory reaction

Measurement of gastric acid might be useful to diagnose early stages of AIG when histological changes are minimal but hypo- or achlorhydria is already present. However, so far there is no technically mature method available [34]. Tube tests are invasive, uncomfortable, and time consuming. Endoscopic sampling of gastric secretion after stimulation with gastrin and further determination of hydrogen ion concentration by titration is accurate but also time consuming and requires technical equipment [35]. However, this method has subsequently been used in several studies [34]. Simple intragastric pH measurement during gastroscopy from aspirates would be quick and cheap, but concerns have been raised that this does not reflect gastric acid secretion or volume of acid secretion [34, 36]. Further studies are needed to test the efficacy and benefit of gastric pH or acid measurement in AIG.

The most sensitive serum biomarker for AIG is PCA [37]. In the past, an immunofluorescence method was used; however, identification of the gastric H/K ATPase as the molecular target for PCA has led to an ELISA, which is more sensitive [38, 39, 40]. Intrinsic factor antibodies have proved to be more specific than PCA; however, sensitivity is very low [41] but rises during progression of disease [42]. A combination of PCA and intrinsic factor antibody [41] with anti-Helicobacter pylori and serum gastrin [42] has been suggested. In the study of Antico, levels of PCA did not correlate significantly with severity of disease [42]. However, in other studies [43], PCA showed a trend towards increase over time with a consecutive decrease, which is probably due to destruction of the targeted organ with progression of disease, as also seen in other autoimmune diseases [44]. Furthermore, these specific autoantibodies can precede clinical symptoms by years, as demonstrated for several other autoimmune disorders [43, 45, 46, 47]. Gastrin and pepsinogen levels are not specific for diagnosis of AIG but predict the level of atrophy. A combination of autoantibodies and gastrin and pepsinogen levels is the so-called GastroPanel test (Biohit, Helsinki, Finland), a noninvasive (ELISA) test for “serological biopsy” for diagnosis of antral, corpus, or multifocal atrophy. Although theoretically quite promising, data in clinical experience are controversial [48, 49, 50]; therefore a recommendation for routine screening use cannot be made.

Cancer and AIG

As for other chronic inflammatory diseases such as hepatitis, colitis, and pancreatitis, patients with AIG have a higher risk of developing cancer within the chronically inflamed tissue. Correa described already in 1988 the possible pathway of gastric cancer development (Correa hypothesis/pathway): chronic inflammation leads to atrophy of the tissue, which is further followed by intestinal metaplasia. This is considered as a precursor lesion [51]. Unknown genetic, metabolic, or environmental triggers lead to the adenocarcinoma sequence, which is also known from colonic cancer [52]. In a meta-analysis in 2012, an annual incidence of gastric adenocarcinoma of 0.27 % per person-year, with an overall relative risk of 6.8 (95 % CI 2.6–18.1) has been shown [53]. Additionally, chronic achlorhydria increases production of gastrin by G‑cells in the antrum, which then stimulates enterochromaffin cells leading to their hyperplasia. Hyperplasia can further develop into gastric carcinoids [54, 55]. Although this is a rare cause (<1 %) of gastric neoplasia [56], it has been shown that 50 % of patients with gastric carcinoid tumors suffer from pernicious anemia [57].

The American Society for Gastrointestinal Endoscopy recommended in 2006 a single endoscopic evaluation for neoplastic lesions after diagnosis of AIG but no routine follow-up [58]. For patients with only simple, linear, or micronodular hyperplasia, a 3- to 5‑year gastroscopic surveillance interval has been suggested [59]; however, if lesions are more extensive, a closer interval might be needed. If extensive atrophy and/or intestinal metaplasia is present, guidelines suggest triannual surveillance gastroscopy; in patients with adenomas or low-grade dysplasia, annually [30, 51]. However, these guidelines are not specific for patients with AIG but for atrophic gastritis in the setting of Helicobacter pylori infection. Particular guidelines for AIG patients are missing.

In summary, AIG is a common cause of iron deficiency. Despite this, it is not mentioned in guidelines for diagnosis of iron deficiency [60, 61] although it has a great impact on therapy of iron deficiency, as oral iron therapy, which is first-line therapy in many countries, is often ineffective. As there is no therapy for AIG itself, patients need to be monitored carefully lifelong for recurrence of iron deficiency and development of vitamin B12 deficiency. Also, the higher risk of gastric neoplasia should not be forgotten.



The endoscopic and histologic pictures were gratefully provided by Dr. Christoph Gasche, Department for Gastroenterology and Hepatology, Medical University of Vienna and Dr. Georg Oberhuber, Department for Pathology, Medical University of Vienna.

Open access funding provided by Medical University of Vienna.

Compliance with ethical guidelines

Conflict of interest

S. Kulnigg-Dabsch declares that she has no competing interests.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Toh BH, Sentry JW, Alderuccio F. The causative H+/K+ ATPase antigen in the pathogenesis of autoimmune gastritis. Immunol Today. 2000;21(7):348–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Faber K. Achylia gastrica mit Anamie. Med Klin. 1909;5:1310–25.Google Scholar
  3. 3.
    Dickey W, et al. Gastric as well as duodenal biopsies may be useful in the investigation of iron deficiency anaemia. Scand J Gastroenterol. 1997;32(5):469–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Hershko C, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica. 2005;90(5):585–95.PubMedGoogle Scholar
  5. 5.
    Shayeghi M, et al. Identification of an intestinal heme transporter. Cell. 2005;122(5):789–801.PubMedCrossRefGoogle Scholar
  6. 6.
    Lombard M, Chua E, O’Toole P. Regulation of intestinal non-haem iron absorption. Gut. 1997;40(4):435–9.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Bezwoda W, et al. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med. 1978;92(1):108–16.PubMedGoogle Scholar
  8. 8.
    Cook JD, Brown GM, Valberg LS. The effect of Achylia Gastrica on iron absorption. J Clin Invest. 1964;43:1185–91.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med. 1968;279(13):672–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Hines JD, Hoffbrand AV, Mollin DL. The hematologic complications following partial gastrectomy. A study of 292 patients. Am J Med. 1967;43(4):555–69.PubMedCrossRefGoogle Scholar
  11. 11.
    Hershko C, Patz J, Ronson A. The anemia of achylia gastrica revisited. Blood Cells Mol Dis. 2007;39(2):178–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Aditi A, Graham DY. Vitamin C, gastritis, and gastric disease: a historical review and update. Dig Dis Sci. 2012;57(10):2504–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Gram K, Gram HC. Relations between achylia gastrica and simple and pernicious anemia. Arch Intern Med (Chic). 1924;34:658–68.CrossRefGoogle Scholar
  14. 14.
    Faber K. Anämische Zustände bei der chronischen Achylia Gastrica. Beriner Klin Wochenschr. 1913;50:958.Google Scholar
  15. 15.
    Annibale B, et al. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med. 2001;111(6):439–45.PubMedCrossRefGoogle Scholar
  16. 16.
    Hershko C, et al. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood. 2006;107(4):1673–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang Y, et al. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev. 2013;22(5):821–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Cabrera de Leon A, et al. Factors associated with parietal cell autoantibodies in the general population. Immunol Lett. 2012;147(1–2):63–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Toh BH, et al. Cutting edge issues in autoimmune gastritis. Clin Rev Allergy Immunol. 2012;42(3):269–78.PubMedCrossRefGoogle Scholar
  20. 20.
    Claeys D, et al. The gastric H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology. 1998;115(2):340–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Centanni M, et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med. 1999;159(15):1726–30.PubMedCrossRefGoogle Scholar
  22. 22.
    Tursi A, et al. Noninvasive prediction of chronic atrophic gastritis in autoimmune thyroid disease in primary care. Scand J Gastroenterol. 2014;49(11):1394–6.PubMedGoogle Scholar
  23. 23.
    Chanarin I. Pernicious anaemia as an autoimmune disease. Br J Haematol. 1972;23(Suppl):101–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Perros P, et al. Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. Diabet Med. 2000;17(10):749–51.PubMedCrossRefGoogle Scholar
  25. 25.
    De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab. 2008;93(2):363–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Kaye PV, et al. The clinical utility and diagnostic yield of routine gastric biopsies in the investigation of iron deficiency anemia: a case-control study. Am J Gastroenterol. 2008;103(11):2883–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Kulnigg-Dabsch S, et al. Autoimmune gastritis is common in patients with iron deficiency – Non-invasive evaluation of iron deficiency aside guideline recommendations. Gastroenterology. 2015;148(4):1.CrossRefGoogle Scholar
  28. 28.
    Toh BH. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev. 2014;13(4–5):459–62.PubMedCrossRefGoogle Scholar
  29. 29.
    Okano A, Takakuwa H, Matsubayashi Y. Parietal-cell hyperplasia mimicking sporadic fundic gland polyps in the atrophic mucosa of autoimmune gastritis. Gastrointest Endosc. 2007;66(2):394–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Neumann WL, et al. Autoimmune atrophic gastritis – pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Park JY, Lam-Himlin D, Vemulapalli R. Review of autoimmune metaplastic atrophic gastritis. Gastrointest Endosc. 2013;77(2):284–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Stolte M, et al. Active autoimmune gastritis without total atrophy of the glands. Z Gastroenterol. 1992;30(10):729–35.PubMedGoogle Scholar
  33. 33.
    Pittman ME, et al. Autoimmune metaplastic atrophic gastritis: recognizing precursor lesions for appropriate patient evaluation. Am J Surg Pathol. 2015;39(12):1611–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Ghosh T, et al. Review article: methods of measuring gastric acid secretion. Aliment Pharmacol Ther. 2011;33(7):768–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Iijima K, et al. A new endoscopic method of gastric acid secretory testing. Am J Gastroenterol. 1998;93(11):2113–8.PubMedCrossRefGoogle Scholar
  36. 36.
    van Herwaarden MA, Samsom M, Smout AJ. 24-h recording of intragastric pH: technical aspects and clinical relevance. Scand J Gastroenterol Suppl. 1999;230:9–16.PubMedCrossRefGoogle Scholar
  37. 37.
    Uibo R, et al. The relationship of parietal cell, gastrin cell, and thyroid autoantibodies to the state of the gastric mucosa in a population sample. Scand J Gastroenterol. 1984;19(8):1075–80.PubMedGoogle Scholar
  38. 38.
    Chuang JS, et al. Diagnostic ELISA for parietal cell autoantibody using tomato lectin-purified gastric H+/K(+)-ATPase (proton pump). Autoimmunity. 1992;12(1):1–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Sugiu K, et al. Evaluation of an ELISA for detection of anti-parietal cell antibody. Hepatogastroenterology. 2006;53(67):11–4.PubMedGoogle Scholar
  40. 40.
    Toh BH, et al. Parietal cell antibody identified by ELISA is superior to immunofluorescence, rises with age and is associated with intrinsic factor antibody. Autoimmunity. 2012;45(7):527–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Lahner E, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104(8):2071–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Antico A, et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol. 2012;2012:520970.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Tozzoli R, et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev. 2010;10(2):80–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Chiovato L, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003;139(5 Pt 1):346–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum. 2007;56(6):1736–44.PubMedCrossRefGoogle Scholar
  46. 46.
    Tozzoli R. The diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases. Clin Chem Lab Med. 2008;46(5):577–87.PubMedCrossRefGoogle Scholar
  47. 47.
    Israeli E, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54(9):1232–6.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Lombardo L, et al. Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test. Clin Chem Lab Med. 2010;48(9):1327–32.PubMedCrossRefGoogle Scholar
  49. 49.
    McNicholl AG, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol. 2014;26(9):941–8.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Graham DY, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol. 2006;4(3):306–14.PubMedCrossRefGoogle Scholar
  51. 51.
    Dinis-Ribeiro M, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74–94.PubMedCrossRefGoogle Scholar
  52. 52.
    Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554–60.PubMedGoogle Scholar
  53. 53.
    Vannella L, et al. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther. 2013;37(4):375–82.PubMedCrossRefGoogle Scholar
  54. 54.
    Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion. 1988;39(2):61–79.PubMedCrossRefGoogle Scholar
  55. 55.
    Bordi C, et al. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol. 1995;19(Suppl 1):S8–19.PubMedGoogle Scholar
  56. 56.
    Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012;2012:287825.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Vannella L, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33(12):1361–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Hirota WK, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63(4):570–80.PubMedCrossRefGoogle Scholar
  59. 59.
    Annibale B, Lahner E, Fave GD. Diagnosis and management of pernicious anemia. Curr Gastroenterol Rep. 2011;13(6):518–24.PubMedCrossRefGoogle Scholar
  60. 60.
    Goddard AF, et al. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309–16.PubMedCrossRefGoogle Scholar
  61. 61.
    Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut. 2000;46(Suppl 3–4):IV1–IV5.PubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2016

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of Medicine IIIMedical University of ViennaViennaAustria

Personalised recommendations